Payer-Negotiated Prices in the Diagnosis and Management of Thyroid Cancer in 2021

Payer-Negotiated Prices in the Diagnosis and Management of Thyroid Cancer in 2021

Thyroid cancer is among the most common malignancies in the US, with a 3.6% annual increase in incidence over the past 50 years. Treatment regimens for thyroid cancer are well-established, with excellent survival outcomes. However, costs of thyroid cancer care can vary substantially by hospital and...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JAMA : the journal of the American Medical Association 2021-07, Vol.326 (2), p.184-185
Hauptverfasser: Xiao, Roy, Rathi, Vinay K, Gross, Cary P, Ross, Joseph S, Sethi, Rosh K. V
Format: Artikel
Sprache:eng
Schlagworte:
Bankruptcy
Cancer
Letter
Letters
Medical diagnosis
Online First
Research Letter
Thyroid
Thyroid cancer
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Thyroid cancer is among the most common malignancies in the US, with a 3.6% annual increase in incidence over the past 50 years. Treatment regimens for thyroid cancer are well-established, with excellent survival outcomes. However, costs of thyroid cancer care can vary substantially by hospital and impose significant financial burdens on patients2; among patients with cancer, bankruptcy rates are highest for those with thyroid cancer.
ISSN:0098-7484
1538-3598
DOI:10.1001/jama.2021.8535